1-3 of 3
Heather K Raymon
Close
Sort by
Journal Articles

CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways

Patrick Hagner, PhD, Maria Wang, PhD, Suzana Couto, PhD, Mike Breider, DVM, PhD DACVP, Celia Fontanillo, PhD, Matthew Trotter, PhD, Chad C Bjorklund, PhD, Courtney G. Havens, PhD, Heather K Raymon, PhD, Rama Krishna Narla, PhD, Leo Barnes, PhD, Michelle Waldman, MS, Tom Daniel, MD, Anke Klippel, PhD, Michael Pourdehnad, MD, Anjan Thakurta, PhD, Rajesh Chopra, MD, PhD, Anita K. Gandhi, PhD
Journal: Blood
Blood (2014) 124 (21): 3035.
https://doi.org/10.1182/blood.V124.21.3035.3035
Published: 2014
Journal Articles

The Novel mTOR Kinase Inhibitor CC-223 Demonstrates Significant Activity In In Vitro Models Of Multiple Myeloma (MM), Both As a Single Agent and In Combination With The Approved Agents, Dexamethasone, Lenalidomide and Pomalidomide

Emily Rychak, Ph.D., Derek Mendy, B.S., Karen Miller, B.S., Jim Leisten, B.S., Rama Krishna Narla, Ph.D., Heather K Raymon, Ph.D., Rajesh Chopra, M.D., Ph.D., Antonia Lopez-Girona, Ph.D.
Journal: Blood
Blood (2013) 122 (21): 3160.
https://doi.org/10.1182/blood.V122.21.3160.3160
Published: 2013
Journal Articles

Sotatercept, an Activin Receptor IIa Ligand Trap, Acts Through Bone Marrow Accessory Cells to Promote Late-Stage Erythropoiesis and a Rapid Induction of Red Blood Cell Number and Hemoglobin

Soraya Carrancio, PhD, Jennifer A Markovics, PhD, Piu Wong, PhD, Jim Leisten, Matthew C Groza, Heather K Raymon, Carla Heise, PhD, Rajesh Chopra, MD, PhD, Tom O Daniel, MD, PhD, Victoria Sung, PhD
Journal: Blood
Blood (2012) 120 (21): 372.
https://doi.org/10.1182/blood.V120.21.372.372
Published: 2012